PMH51 Measuring Relapse After Substance Abuse Treatment: A Proportional Hazard Approach  by Ciesla, J. & Mazurek, K.
groups are described here for children (proxy EQ-5D and KS) and parents (EQ-5D).
Optimal compliance: proxy EQ-5D 0.8257, KS 47.5152, EQ-5D 0.8331. Suboptimal
compliance: proxy EQ-5D 0.7321, KS 42.7671, EQ-5D 0.8050. Medication use stopped:
proxy EQ-5D 0.7635, KS 42.5969, EQ-5D 0.8169. Remission after medication use:
proxy EQ-5D 0.8518, KS 45.8929, EQ-5D 0.8220. Naïve to medication: proxy EQ-5D
0.7719, KS 43.3744, EQ-5D 0.7899. CONCLUSIONS: Children with a good compliance
to medication and naïve children have a better QoL compared to non-compliant
children and children who stopped treatment (non-remission). The QoL of children
in remission is better than the QoL of children using medication. QoL of parents
follows a similar pattern.
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OBJECTIVES: To test the characteristics of a QUICK Questionnaire-Short version
(Q10) as diagnostic instrument for wearing-off phenomenon (WO) in Parkinson’s
disease (PD) patients. METHODS: Observational, cross-sectional, multicenter, and
national study developed in clinical practice. The study was developed in two
consecutive phases: I, to determine the sensitivity and specificity of Q10; and II: to
assess the usefulness (investigators) and the ability and ease of use (patients) of
Q10 questionnaire. Furthermore, the prevalence of WO among PD patients consec-
utively attending the specialist was also assessed (phase II). Patients 30 years old
at the onset of the disease with5 years from diagnosis and under treatment were
selected.RESULTS: In phase I, 162 patients were included, 67.49.7 years old, 53.8%
males, and 3.11.4 years from diagnosis. Most of them (85%) were in Hoehn-Yahr
stage 2-3. WO was presented in 64.8% (33.3% mild; 31.5% moderate/severe). Q10
was completed in 6.64.9 minutes. With two positive responses the Q10 showed
good sensitivity (90%) and moderate specificity (70%) and with 3 positive responses
both values reached an arbitrarily hypothesized 75% threshold (sensitivity: 81%;
specificity: 75%). The mean usefulness Q10 score was good [7.3 (1.6), scale 1-10]. In
phase II, most patients considered Q10: easy to understand (80.6%), reflect their
present situations (78.8%), and useful to communicate discomfort to the doctor
(80.6%). The prevalence of WO among the total PD patients attending to the neu-
rologist was of 59.0%, higher in males (64.9%), Hoehn-Yahr staging (80%, 3-4 stage)
and in patients with more time of PD evolution (71.9%). CONCLUSIONS: The Q10 is
a useful instrument for screening and diagnosis of WO, showing good sensitivity
and specificity, as well as, good usefulness, ability and ease to use. Almost two out
of three PD patients attending to the neurologist presented WO.
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OBJECTIVES: Develop a cross-cultural adaptation, English to Spanish, of the Clin-
ically Useful Depression Outcome Scale (CUDOS): a validated instrument to assess
depressive symptoms in patients with major depressive disorder (MDD).
METHODS: CUDOS is a brief self-administered scale with 18 items assessing all of
the DSM-IV inclusion criteria for MDD, psychosocial impairment and patients’
quality of life. Three independent translators (2 Spanish and 1 English) performed
forward-backward translations of the original scale. Draft version was reviewed by
an expert panel (4 general practitioners, 1 psychiatrist, and 2 psychologists) and
tested in 19 adult patients with MDD. Regarding experts’ and patients’ responses,
comprehension and importance (C/I) of each item were evaluated using a Likert
scale ranging from 0 (lowest level of C/I) to 4 (highest level of C/I). Furthermore,
feasibility, ceiling and floor effects and reliability were preliminary analyzed.
RESULTS: According to experts’ criteria, mean C/I values of items were over 2
points (comprehension mean range: 3.25-4 & importance mean range: 2.5-4). Re-
garding patients’ responses, acceptable mean values in comprehension (range:
2.26-3.37) were obtained. However, 4 items were modified to improve comprehen-
sion: loss of interest in usual activities, psychomotor retardation, indecisiveness
and hopelessness Patients reported low importance scores in items related to
thoughts of death (mean 1.42), suicidal ideation (mean 1.26), guilt (mean 1.79),
hypersomnia (mean 1.37) and insomnia (mean 1.78). Missing data was only
found in 2 patients. Internal consistency was high (Cronbach  .886), Neither item
ceiling nor floor effects were observed and patients perceiving a moderate to severe
psychosocial impairment obtained higher CUDOS scores –indicating a higher im-
pact- than those with mild or null impairment (Mann-Whitney U9.500; p.019).
Finally, the Spanish version of the CUDOS was reached by consensus.
CONCLUSIONS: The original CUDOS instrument was culturally adapted into Span-
ish. Psychometric analyses are needed to validate this measure in Spain.
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OBJECTIVES: FDA guidance on the use of Patient Reported Outcomes (PRO) for
product labeling claims emphasizes the importance of documented evidence of
patient input in PRO instrument development. A review of existing PROs used in
Major Depressive Disorder (MDD) suggested the need to conduct qualitative re-
search with patients with MDD to better understand their experience of MDD and
develop an evaluative instrument with content validity. The aim of this study was
to develop such a measure. METHODS: Ten MDD severity-specific focus groups
(n3-4 patients per group; total n38) with adult patients between the ages of 18
and 65 having a clinician-confirmed diagnosis of MDD and varying in severity
levels as defined by the DSM-IV TR criteria were conducted in January 2009.
Grounded theory data collection and analysis methods were used including an
open-ended discussion guide, an iteratively developed coding scheme, and the
comparison of coded segments of patients’ quotes to identify the patient experi-
enced signs and symptoms of MDD. Saturation of concepts, where no new relevant
information emerges in later interviews, was assessed. A new PRO instrument for
MDD was developed; cognitive interviews (n20) were conducted to test its content
validity in terms of item relevance and comprehension, comprehensiveness, in-
structions, recall period and response categories.RESULTS:Thirty-five unique con-
cepts falling into the following 6 domains: emotional symptoms; ideation symp-
toms; neuro-vegetative or somatic symptoms; physical impact; social impact; and
cognitive impact were elicited. Concept saturation was achieved for each of the
symptom concepts across severity levels. The MDD PRO instrument includes 15
daily and 21 weekly items. Cognitive interviews supported its content validity.
Items were revised, deleted, or moved from daily to weekly assessment based on
cognitive interview results CONCLUSIONS: Rigorous qualitative research resulted
in the development of a PRO measure for MDD with supported content validity; its
psychometric properties and responsiveness requires assessment.
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DIFFERENCES BETWEEN OPIOID DEPENDENT PATIENTS IN ITALY AND
GERMANY RECEIVING SUBSTITUTION THERAPY
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OBJECTIVES: Substitution therapy is commonly used across the world for the treat-
ment of opioid dependence (OD), yet little evidence exists examining country-
specific differences between acceptance and effectiveness of this treatment. The
purpose of this study was to examine differences between patient demographics,
treatment accessibility, and attitudes toward substitution therapy among OD pa-
tients in Germany and Italy.METHODS:A telephonic survey, initiated by the Italian
Federation of Operators of Dependences Departments and Services, examining
substitution therapy was administered to OD patients across two countries: Ger-
many (n200) and Italy (n378). The survey assessed experiences prior to and
during substitution therapy. RESULTS: Italian patients reported being in better
physical and mental health than German patients (p’s 0.001); were more likely to
get information about substitution therapy from family members than German
patients (8.9% vs. 3.2%, 2  5.22; p  0.05); and were more likely to report that it
was either very easy or fairly easy to find a doctor from whom they could receive
substitution treatment than German patients (89.9% vs. 68.7%, 2  40.35; p 
0.001). In contrast, German patients were more likely to get information from other
drug users (63.9% vs. 47.7%, 2 10.72; p 0.01) or their family physicians (14.6% vs.
4.3%, 2  14.59; p  0.0001), and were also more likely than Italian patients to
misuse their substitution drug by either snorting (11.5% vs. 3.2%, 2  15.94; p 
0.0001) or injecting it (18.5% vs. 11.1%, 2  6.05; p  0.05). CONCLUSIONS: The
present results highlight key differences in patient attitudes and experiences re-
garding substitution therapy. Differences in social and institutional attitudes, in
addition to cultural norms and health care policies, may explain the present find-
ings, which demonstrate the complexity of the OD population.
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OBJECTIVES: This research uses Cox regression to analyze relapse patterns of
adults treated for substance use disorder (SUD). The objective is to evaluate the role
psychosocial, treatment and environmental characteristics play in the relapse pro-
cess. While relapse is a much-studied phenomenon, there is no research describing
in detail how the risk of relapse changes over time (especially in the months im-
mediately following primary treatment) given known protective factors. Since SUD
is a chronic relapsing disorder, it is important to understand ways treatment gains
can be maintained. METHODS: Subjects are 408 adults discharged between 2000-
2009 from an ASAM-defined Level 1.A primary inpatient treatment program. Data
were collected via a 215-item questionnaire as part of the treatment program’s
annual outcomes evaluation. The sampling frame was people who successfully
completed treatment and who gave consent. The response rate was 56 percent. The
researchers obtained the treatment records of each person completing the ques-
tionnaire and matched the treatment outcomes from the questionnaire to treat-
ment and sociodemographic variables present in the treatment records. A compre-
hensive data set was created from these two sources. Data were analyzed using
Cox proportional hazard regression. RESULTS: Statistically significant covariates
include: home environment variables (those with supportive people at home are
3.17 times less likely to relapse; those with supportive spouses are 4.91 times less
likely to relapse) and support group variables (those attending self-help meetings
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are 1.61 times less likely to relapse; those with sponsors are 1.64 times less likely to
relapse), cetertis paribus. Adjustor covariates include: Global Assessment of Func-
tioning, addiction severity, DSM diagnosis and length of stay. CONCLUSIONS:
Since this survival model relates the time that passes before relapse occurs to
known risk factors for relapse, this research will help treatment providers identify
not only the best types of interventions but also the correct timing of interventions.
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OBJECTIVES: In previous studies, psychopathology particularly negative, depres-
sive and cognitive syndromes adversely influenced health-related quality of life
(HRQoL). The objective of the study was to examine the relationship between
schizophrenia symptoms and the HRQoL dimensions of the EQ-5D descriptive
system. METHODS: This was a cross-sectional study conducted at the Psychiatric
Clinic, Universiti Kebangsaan Malaysia Medical Centre. Patients were assessed for
symptom severity using the Clinical Global Impressions-Schizophrenia (CGI-SCH)
severity scale (scores range from (1) no illness to (7) most severe possible) by the
attending clinicians. Patients’ perceived health states in 5 dimensions (mobility,
self-care, usual activities, pain/discomfort and anxiety/depression) with 3 levels of
response; (1) no problems, 2 (moderate problems) and 3 (extreme problems) were
evaluated using the EQ-5D descriptive system. The association between the 2
scales were examined by Spearman rank correlations. RESULTS: A total of 222
out-patients (Mean age 37.7, SD 10.1; Mean duration of illness  11.42, SD8.0)
with a DSM-IV chart diagnosis of schizophrenia participated in the study. There
was a moderate positive correlation between the EQ-5D ‘usual activities’ dimen-
sion and each of the CGI-SCH overall, depressive and cognitive symptom dimen-
sion scores (rs  0.35, 0.37 and 0.31, respectively & for all p  0.01). A significant
moderate correlation was also found between the EQ-5D ‘anxiety/depression’ and
the CGI-SCH depressive symptom dimension scores (rs  0.35, p  0.01). Weak
correlations were found between the CGI-SCH symptoms and other EQ-5D dimen-
sions scores (rs ranges from 0.16 to 0.26, p 0.01). CONCLUSIONS: In chronic
schizophrenics living in the community, worsening of overall, depressive and cog-
nitive symptoms were moderately associated with deterioration in patients’ usual
life activities and worsening of depressed mood was moderately associated with
worsening of anxiety or depression states. Schizophrenia syndromes were only
weakly associated with patients’ mobility, self-care and sense of pain or discom-
fort.
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FOLLOW-UP OF HEALTH-RELATED QUALITY OF LIFE IN YOUNG HEROIN USERS
Català L1, Ferrer M1, Sanchez-Niubò A1, Brugal MT2, Domingo-Salvany A3, Itinere I4
1IMIM-Hospital del Mar, Barcelona, -, Spain, 2Agència de Salut Publica de Barcelona, Barcelona,
-, Spain, 3IMIM-Hospital del Mar & CIBERESP, Barcelona, -, Spain, 4Instituto de Salud Carlos III,
Madrid, -, Spain
OBJECTIVES: To ascertain changes in Health related Quality of Life (HRQL) among
young heroin users after one year follow-up.METHODS:Heroin users (18-30y) were
recruited in outdoor settings in three Spanish cities (Barcelona, Madrid, Seville)
from 2001 to 2003 and followed up, on average, 1.4(SD:0.6) years later. Standardised
laptop interviews included socio-demographic data, drug use patterns, health re-
lated issues, the Severity of Dependence Scale (SDS) and the Nottingham Health
Profile (NHP). For bivariate analyses, non parametric Mann-Whitney U and
Kruskal-Wallis tests were used. Factors associated to NHP score changes over time
were analysed through a multiple linear regression taking into account socio-de-
mographic factors, consumption patterns and health related variables.RESULTS:A
total of 628 subjects (72.5% males), mean age 27.9 (SD:3.4) years were followed
(63.4%). Mean total NHP score improved, from 36.4 (SD:24.2) at baseline to 27.0
(SD:22.4) at follow-up. Variables associated with total NHP score worsening were
HIV infection during follow-up, having experienced an overdose during the last 12
months and psychiatric treatment ever; conversely, total NHP score improved
among those who got a job by the end of the study. Each additional substance with
a weekly regular use and higher SDS scores for both cocaine and heroin, measured
as a difference from baseline values, were also related to worsening total NHP
score. We observed an interaction between severity of heroin dependence (as mea-
sured with SDS) and methadone maintenance treatment. The NHP total score only
improved, with decreasing heroin SDS, among drug users in methadone mainte-
nance treatment.CONCLUSIONS:HRQL improved over 12 months for young heroin
users. The main variables independently related with HRQL were changes in her-
oin and cocaine SDS. Further holistic models taking into account social variables
are needed.
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OBJECTIVES: Developing practical strategies to incorporate quality of life (QoL)
data in clinical management is an unmet need, and using quality of life (QoL) as a
predictor of clinical event is a new trend in outcomes research. The objective of this
study was to investigate relapse rate as a function of QoL in schizophrenic patients.
METHODS: We used data from EuroSC, a multicenter 2-year cohort study con-
ducted in France, England and Germany. We first examined the association be-
tween occurrence of relapse and baseline QoL, as measured by SF36 mental com-
posite score (MCS) and physical composite score (PCS), by EQ-5D and QOLI
subjective score. Then bivariate analyses were performed to identify confounding
factors (CF). Finally CF and QoL were incorporated in several multivariate Cox
models. RESULTS: Our sample consisted in 922 patients with schizophrenia. QoL
was found to be lower for those who relapsed (418 patients with MCS 40.1, PCS
47.1, EQ-5D utility  0.70 and QOLI  4.65 vs. 504 patients with MCS  43.9
(p0.0001), PCS  49.2 (p0.001), EQ-5D utility  0.77 (p0.0001), and QOLI  4.8
(p0.01)). Bivariate analyses identified several outcomes: age, gender, severity of
disease, depression, antipsychotic medication, compliance, subjective side effects
and functioning. Multivariate Cox models confirmed that a higher level of QoL
predicts a significantly lower rate of relapse at 2 years (HR  0.94, p0.03 for MCS;
HR 0.89; p0.01 for PCS; HR0.97; p0.001 for EQ-5D utility; HR0.83; p0.004 for
QOLI). CONCLUSIONS: This study shows that QoL can be considered as a mediator
of relapse in schizophrenia, independently of clinical severity scales. These results
are consistent with new research trends. Our findings can contribute to develop
credible strategies on how to integrate QoL data in clinical practice.
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AN EXAMINATION OF ANTIDEPRESSANT-RELATED SEXUAL DYSFUNCTION
AND DEGREE OF ENJOYMENT AND SATISFACTION WITH DAILY ACTIVITIES,
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OBJECTIVES: To understand the association of antidepressant-related sexual dys-
function with degree of enjoyment and satisfaction from daily activities, and cur-
rent medication. METHODS: Employed individuals (18 years of age) with depres-
sion (excluding bipolar disorder) completed a web-based computer-generated 25-
minute survey (population identified by Harris Interactive). Sexual dysfunction
(SD) was assessed using the Arizona Sexual Experience (ASEX) Scale on 5 compo-
nents of sexual functioning (Drive, Arousal, Penile Erection/Vaginal Lubrication,
Orgasm, Satisfaction); each rated on a 6-level ordinal scale (higher scores indicate
increased SD). Using distribution among current antidepressant users, overall SD
score was categorized into quartiles (lowest quartile represented better sexual
functioning). Degree of enjoyment and satisfaction related to general activity and
current medication was measured using a 5-point ordinal scale (1very poor and
5very good) using the Quality of Life Enjoyment and Satisfaction Questionnaire –
Short Form (QLESQ-SF). A summary “percent-of-max” score for general activity
items, transformed to 5-level ordinal variable employing cut-points of 20, 40, 60
and 80%, was used (20% represented the poorest experience). Gender stratified
cumulative logit models were used to estimate effect of SD on QLESQ measures.
RESULTS: Of 1,521 respondents, 872 (57%) reported current antidepressant use
(60.6% female, mean age 49.9 13.5 years). Among antidepressant users, compared
to the first SD quartile, odds of being in a poorer overall “percent-of-max” score (i.e.,
lower enjoyment/satisfaction) were greater in the highest (4th) SD quartile for both
males (odds ratio [OR] 3.03; p0.0007) and females (OR1.96; p0.0021). Sexual
dysfunction was associated with lack of satisfaction with medication for both gen-
ders: (males - 3rd SD quartile (OR2.17; p0.001); highest SD quartile (OR3.33;
p0.0003); females - highest SD quartile (OR1.49; p0.06)). CONCLUSIONS: These
data suggest that antidepressant-related SD may be associated with diminished
enjoyment and satisfaction with daily activities and current medication. Such per-
ceptions may impact eventual treatment outcomes.
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OBJECTIVES: There has been increased attention to the antipsychotic treatment of
negative symptoms in schizophrenia and the potential impact that this could have
on various functional outcomes. We compared the relative effects of negative
symptoms on functioning as compared to other symptoms. METHODS: Data are
from 18 months of the National Institute of Mental Health (NIMH) CATIE trial of
chronic schizophrenia (n1447). Measures were the Positive and Negative Syn-
drome Scale (PANSS), functioning from the Heinrich’s (Instrumental role, Common
place objects and activities) and items from the Lehman Quality of Life Scales
(Leisure activities, Instrumental activities of daily living). Quality of life items mea-
suring negative symptoms were excluded. Correlations between the five PANSS
factors and the functional measures were examined at baseline and change. Func-
tioning items were summed to create a standardized total score. Multiple regres-
sion was used to predict the functioning total score at baseline using the five PANSS
factors and change in functioning using change on the PANSS factors. RESULTS:
The negative symptom factor correlated more strongly than other symptom fac-
tors with functioning at baseline and change scores. Multiple regression predicting
functioning at baseline including all five PANSS factors showed that the negative
symptom factor was the strongest predictor, almost three times that of positive
symptoms (r-0.25 vs. r-0.07). A similar multiple regression predicting change in
total functioning with change on PANSS also found that the negative factor was the
best predictor and was double that of the positive factor (r-0.08 vs. r-0.045).
CONCLUSIONS: Baseline and change in functioning were more strongly related to
the PANSS negative factor than the other four PANSS factors. Since we focused on
negative symptoms we chose domains of functioning that did not overlap with
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